Passage Bio debuts with $115.5M for CNS gene therapies

Co-founded by gene therapy pioneer James Wilson, Passage Bio Inc. (Philadelphia, Pa.) launched with $115.5 million in series A funding Feb 14. Passage is developing five adeno-associated viral gene therapies to treat rare monogenic CNS diseases under a research collaboration and license with University of Pennsylvania.

OrbiMed Advisors led the series A round, with participation from Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures...